AU9149791A - Synergistic compositions of soluble complement receptors and compounds that inhibit complement and/or suppress immune activity - Google Patents

Synergistic compositions of soluble complement receptors and compounds that inhibit complement and/or suppress immune activity

Info

Publication number
AU9149791A
AU9149791A AU91497/91A AU9149791A AU9149791A AU 9149791 A AU9149791 A AU 9149791A AU 91497/91 A AU91497/91 A AU 91497/91A AU 9149791 A AU9149791 A AU 9149791A AU 9149791 A AU9149791 A AU 9149791A
Authority
AU
Australia
Prior art keywords
group
complement
composition
activity
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU91497/91A
Other languages
English (en)
Inventor
Patrick C. Kung
Henry C. Marsh Jr.
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
T Cell Sciences Inc
Original Assignee
T Cell Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by T Cell Sciences Inc filed Critical T Cell Sciences Inc
Publication of AU9149791A publication Critical patent/AU9149791A/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A61K38/166—Streptokinase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/49—Urokinase; Tissue plasminogen activator
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Transplantation (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU91497/91A 1990-12-06 1991-12-06 Synergistic compositions of soluble complement receptors and compounds that inhibit complement and/or suppress immune activity Abandoned AU9149791A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US62387890A 1990-12-06 1990-12-06
US623878 1990-12-06

Publications (1)

Publication Number Publication Date
AU9149791A true AU9149791A (en) 1992-07-08

Family

ID=24499761

Family Applications (1)

Application Number Title Priority Date Filing Date
AU91497/91A Abandoned AU9149791A (en) 1990-12-06 1991-12-06 Synergistic compositions of soluble complement receptors and compounds that inhibit complement and/or suppress immune activity

Country Status (6)

Country Link
EP (1) EP0560929A1 (fr)
JP (1) JPH06503344A (fr)
KR (1) KR930703011A (fr)
AU (1) AU9149791A (fr)
CA (1) CA2097825A1 (fr)
WO (1) WO1992010205A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU685433B2 (en) * 1993-02-12 1998-01-22 Regents Of The University Of Minnesota Pulmonary administration of sCR1 and other complement inhibitory proteins

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5506247A (en) * 1988-04-15 1996-04-09 T Cell Sciences, Inc. Compounds that inhibit complement and/or suppress immune activity
US5173499A (en) * 1988-04-15 1992-12-22 T Cell Sciences, Inc. Compounds which inhibit complement and/or suppress immune activity
US5366986A (en) * 1988-04-15 1994-11-22 T Cell Sciences, Inc. Compounds which inhibit complement and/or suppress immune activity
DE4222534A1 (de) 1992-07-09 1994-01-13 Behringwerke Ag Verwendung von Komplement-Inhibitoren zur Herstellung eines Arzneimittels zur Prophylaxe und Therapie von entzündlichen Darm- und Hauterkrankungen sowie Purpura
US5456909A (en) * 1992-08-07 1995-10-10 T Cell Sciences, Inc. Glycoform fractions of recombinant soluble complement receptor 1 (sCR1) having extended half-lives in vivo
GB9301289D0 (en) * 1993-01-22 1993-03-17 Smithkline Beecham Plc Novel composition
US5837499A (en) * 1993-12-06 1998-11-17 Ciba-Geigy Corporation DNA encoding C5A receptor antagonists having substantially no agonist activity and methods of expressing same
US5807824A (en) * 1993-12-06 1998-09-15 Ciba-Geigy Corporation C5A receptor antagonists having substantially no agonist activity
US5627264A (en) * 1994-03-03 1997-05-06 Alexion Pharmaceuticals, Inc. Chimeric complement inhibitor proteins
EP2815767A1 (fr) * 2004-05-14 2014-12-24 Alexion Pharmaceuticals, Inc. Prolongation de la survie d'un allogreffon par inhibition d'activité complémentaire
KR101650264B1 (ko) 2006-03-02 2016-08-22 알렉시온 파마슈티칼스, 인코포레이티드 보체 활성을 저해함으로써 동종이식편의 생존 연장
EP3124029A1 (fr) 2006-03-15 2017-02-01 Alexion Pharmaceuticals, Inc. Traitement de patients souffrant d'hémoglobinurie paroxystique nocturne par un inhibiteur de complément
AU2007293013B2 (en) 2006-09-05 2013-06-27 Alexion Pharmaceuticals, Inc. Method and compositions for the treatment of antibody mediated neuropathies
LT2894165T (lt) * 2008-11-10 2023-03-10 Alexion Pharmaceuticals, Inc. Būdai ir kompozicijos, skirti su komplementu susijusių sutrikimų gydymui
EP3011345B1 (fr) 2013-08-07 2017-10-04 Alexion Pharmaceuticals, Inc. Protéines de bio-marqueurs de syndrome hémolytique et urémique atypique
GB201800620D0 (en) 2018-01-15 2018-02-28 Univ Manchester C3b Binding Polypeptide

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4727018A (en) * 1984-05-18 1988-02-23 Eichner Ronald D Immunoregulation of transplantable tissue
EP0309602B1 (fr) * 1987-09-30 1993-03-24 MUCOS EMULSIONSGESELLSCHAFT m.b.H. Utilisation d'enzymes catabolisantes pour la fabrication d'un médicament destiné au traitement du syndrome d'immunodéficience acquis (SIDA) et leurs stades préliminaires (LAS, ARC)
US5256642A (en) * 1988-04-01 1993-10-26 The Johns Hopkins University Compositions of soluble complement receptor 1 (CR1) and a thrombolytic agent, and the methods of use thereof
IL89790A (en) * 1988-04-01 2002-05-23 Johns Hopking University Sequences of nucleic acids encoding and cells producing CR1 protein and methods for its production and purification
US4895872A (en) * 1989-03-15 1990-01-23 Cetus Corporation Immunosupressive analogues and derivatives of succinylacetone
US5084482A (en) * 1990-04-10 1992-01-28 The Lithox Corporation Methods for inhibiting inflammatory ischemic, thrombotic and cholesterolemic disease response with methionine compounds

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU685433B2 (en) * 1993-02-12 1998-01-22 Regents Of The University Of Minnesota Pulmonary administration of sCR1 and other complement inhibitory proteins

Also Published As

Publication number Publication date
EP0560929A4 (fr) 1994-08-31
CA2097825A1 (fr) 1992-06-07
KR930703011A (ko) 1993-11-29
JPH06503344A (ja) 1994-04-14
WO1992010205A1 (fr) 1992-06-25
EP0560929A1 (fr) 1993-09-22

Similar Documents

Publication Publication Date Title
AU9149791A (en) Synergistic compositions of soluble complement receptors and compounds that inhibit complement and/or suppress immune activity
Vargaftig et al. PAF-acether today—relevance for acute experimental anaphylaxis
KR102362277B1 (ko) 면역조절제로서 1,2,4-옥사디아졸 유도체
AU2004201789B2 (en) Fc receptor modulators and uses thereof
JP6871310B2 (ja) ジペプチド及びトリペプチドエポキシケトンプロテアーゼ阻害剤
KR20160075506A (ko) 면역조절제로서 사이클릭 펩티도미메틱 화합물
EP0984981A1 (fr) Derives anti-inflammatoires de tyrosine
KR20030051882A (ko) Ｌｆａ-1 대항제 화합물
AU663066B2 (en) Compounds that inhibit complement and/or suppress immune activity
US5808109A (en) Compounds that inhibit complement and/or suppress immune activity
JP6650942B2 (ja) Ｎ−（４−ヒドロキシ−４−メチル−シクロへキシル）−４−フェニル−ベンゼンスルホンアミド化合物、及びｎ−（４−ヒドロキシ−４−メチル−シクロへキシル）−４−（２−ピリジル）−ベンゼンスルホンアミド化合物、ならびにこれらの治療上の使用
Bierer et al. The effect of desferrithiocin, an oral iron chelator, on T-cell function
US5401767A (en) Compounds which inhibit complement and/or suppress immune activity
JPH09511761A (ja) 抗癌−、抗ウィルス−および植物生長抑制作用をもつ治療用カシノイド製剤
RU2756055C2 (ru) Гетероциклические соединения и их применение
KR0185226B1 (ko) 이식 조직의 거부반응 억제제 및 il-1 생산 억제제
WO2021096988A1 (fr) Formes salines cristallines d'acide (z)-4-(5- ((3-benzyl-4-oxo-2-thioxothiazolidin-5-ylidène)méthyl)furan-2-yl)benzoïque
JPH06271533A (ja) 免疫抑制剤としての新規なアミノメチレン誘導体
WO2007132179A2 (fr) Agents thérapeutiques
Brás et al. Nitric oxide regulates clonal expansion and activation-induced cell death triggered by staphylococcal enterotoxin B
WARE et al. LYMPHOKINES, VOL. 14
JP2001521895A (ja) 新規金属錯体
JPH08505867A (ja) 炎症治療用の可溶性補体レセプター１（ｓｃｒ−１）とアミジノフェニルまたはアミジノナフチルエステルの組み合わせ
CN118139854A (zh) Ccr6受体调节剂
JPWO2020208088A5 (fr)